Medical utility of apoe allele determination in assessing the need for antioxidant therapy

被引:14
作者
Dreon, DM
Peroutkal, SJ
机构
[1] Menlo Park
关键词
D O I
10.1054/mehy.2000.1213
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The APOE epsilon4 allele is associated with a variety of conditions such as Alzheimer's disease, coronary artery disease, stroke and postoperative cognitive dysfunction, The common pathophysiological feature that appears to explain these positive clinical associations with APOE epsilon4 allele may relate to the decreased endogenous antioxidant c;capability of an individual. A significant body of existing clinical data supports the assumption that diseases associated with the epsilon4 allele can be alleviated by antioxidant therapies, such as vitamin E. Therefore, we hypothesize that determination of an individual's APOE allele status has medical utility as an efficient method to identify patient subgroups susceptible to oxidative damage. We suggest that prospective studies are needed to determine if individuals at high risk for diseases characterized by oxidative damage and/or who have an APOE epsilon4 allele might benefit significantly from available antioxidant intervention at a relatively early and asymptomatic age. (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:357 / 359
页数:3
相关论文
共 32 条
[1]   Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition [J].
Bales, KR ;
Verina, T ;
Dodel, RC ;
Du, YS ;
Altstiel, L ;
Bender, M ;
Hyslop, P ;
Johnstone, EM ;
Little, SP ;
Cummins, DJ ;
Piccardo, P ;
Ghetti, B ;
Paul, SM .
NATURE GENETICS, 1997, 17 (03) :263-264
[2]  
Barger SW, 1997, J NEUROCHEM, V69, P60
[3]  
BENSON RT, 1999, 51 ANN M AM AC NEUR
[4]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[5]   PROTECTIVE EFFECT OF APOLIPOPROTEIN-E TYPE-2 ALLELE FOR LATE-ONSET ALZHEIMER-DISEASE [J].
CORDER, EH ;
SAUNDERS, AM ;
RISCH, NJ ;
STRITTMATTER, WJ ;
SCHMECHEL, DE ;
GASKELL, PC ;
RIMMLER, JB ;
LOCKE, PA ;
CONNEALLY, PM ;
SCHMADER, KE ;
SMALL, GW ;
ROSES, AD ;
HAINES, JL ;
PERICAKVANCE, MA .
NATURE GENETICS, 1994, 7 (02) :180-184
[6]   GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].
CORDER, EH ;
SAUNDERS, AM ;
STRITTMATTER, WJ ;
SCHMECHEL, DE ;
GASKELL, PC ;
SMALL, GW ;
ROSES, AD ;
HAINES, JL ;
PERICAKVANCE, MA .
SCIENCE, 1993, 261 (5123) :921-923
[7]  
CORRIGAN FM, 1991, ANN NY ACAD SCI, V640, P250
[8]   STATEMENT ON USE OF APOLIPOPROTEIN-E TESTING FOR ALZHEIMER-DISEASE [J].
FARRER, LA ;
BRIN, MF ;
ELSAS, L ;
GOATE, A ;
KENNEDY, J ;
MAYEUX, R ;
MYERS, RH ;
REILLY, P ;
RISCH, NJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (20) :1627-1629
[9]   Apolipoprotein E-ε4 genotype predicts a poor outcome in survivors of traumatic brain injury [J].
Friedman, G ;
Froom, P ;
Sazbon, L ;
Grinblatt, I ;
Shochina, M ;
Tsenter, J ;
Babaey, S ;
Ben Yehuda, A ;
Groswasser, Z .
NEUROLOGY, 1999, 52 (02) :244-248
[10]   ALZHEIMERS-DISEASE WITH AND WITHOUT COEXISTING PARKINSONS-DISEASE CHANGES - APOLIPOPROTEIN-E GENOTYPE AND NEUROPATHOLOGIC CORRELATES [J].
GEARING, M ;
SCHNEIDER, JA ;
REBECK, GW ;
HYMAN, BT ;
MIRRA, SS .
NEUROLOGY, 1995, 45 (11) :1985-1990